Selank

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Selank?

Selank (TP-7) is a synthetic heptapeptide developed by the Institute of Molecular Genetics at the Russian Academy of Sciences. It is structurally based on tuftsin — an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) naturally produced during immunoglobulin G cleavage — with a Pro-Gly-Pro stabilising extension that increases metabolic stability and confers distinct neuropeptide activity. Selank peptide was designed to combine anxiolytic and nootropic properties without the sedation, cognitive impairment, or dependence associated with benzodiazepine-class anxiolytics.[1][3]

Approved in Russia as an anxiolytic nasal spray since 2009, Selank occupies a unique position in the neuropeptide landscape: it is one of very few peptide-based compounds to achieve regulatory approval specifically for anxiety disorders. Its dual mechanism — combining the immunomodulatory heritage of its tuftsin backbone with GABAergic, serotonergic, and dopaminergic modulation — distinguishes it from conventional anxiolytics and from other research peptides such as BPC-157 or GHK-Cu that operate through entirely different pathways.[1][2][5]

Despite its Russian clinical approval, Selank remains largely unfamiliar in Western research circles. The majority of published clinical data exists in Russian-language journals, and it has not pursued FDA or EMA regulatory pathways. This creates an unusual evidence profile: genuine regulatory validation in one jurisdiction alongside limited peer-reviewed visibility in another.

Compound Profile

What Does Selank Actually Do?

At its core, Selank is an anxiolytic neuropeptide — sometimes referred to as the “anti-anxiety peptide” in the research community. In clinical studies conducted in Russia, it demonstrated anxiolytic effects comparable to phenazepam (a benzodiazepine) but without the sedation, cognitive impairment, or dependence that define benzodiazepine pharmacology.[3] This is its most distinctive pharmacological feature: Selank anxiety reduction operates through a fundamentally different mechanism than traditional anxiolytics.

The compound modulates multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and noradrenergic pathways are all influenced, creating a broad modulatory profile rather than the targeted receptor agonism seen with benzodiazepines or SSRIs.[1] This multi-system modulation may explain why Selank nootropic effects have been observed alongside its anxiolytic activity: reducing anxiety without sedation can itself improve cognitive performance, particularly under stress conditions.

Beyond its neurological effects, Selank retains the immunomodulatory activity of its parent peptide tuftsin. It influences IL-6 expression and inflammatory gene dynamics, connecting its neuropeptide activity to immune system modulation in a way that few other anxiolytic compounds achieve.[2][5] This dual anxiolytic-immunomodulatory profile makes Selank genuinely novel — it is not simply another anxiolytic, but a compound that bridges the neuroimmune interface.

How Selank Works

Selank’s mechanism begins with its structural heritage. The first four residues (Thr-Lys-Pro-Arg) comprise tuftsin — an endogenous tetrapeptide cleaved from the Fc domain of immunoglobulin G that serves as a natural immunomodulatory signal. Siebert et al. (2017) comprehensively reviewed tuftsin’s properties, documenting its role in macrophage activation, phagocytosis enhancement, and immune regulation.[2] By building on this immunopeptide scaffold, Selank inherits baseline immunomodulatory activity while the Pro-Gly-Pro extension confers both metabolic stability and distinct neuropeptide properties.

Vyunova et al. (2018) provided the most comprehensive review of Selank peptide‘s molecular mechanisms, establishing that the heptapeptide modulates GABAergic neurotransmission, influences serotonin and dopamine metabolism, and affects the expression of brain-derived neurotrophic factor (BDNF) and related signalling cascades.[1] The anxiolytic effect appears to involve allosteric modulation of GABA-A receptor sensitivity rather than direct agonism — a mechanistic distinction from benzodiazepines that may explain the absence of sedation and dependence.

Medvedev et al. (2014) provided direct clinical evidence, comparing Selank to phenazepam in patients with generalised anxiety disorder. The study found comparable anxiolytic efficacy with significantly better tolerability — no sedation, no cognitive impairment, and no withdrawal symptoms upon discontinuation.[3] This clinical head-to-head comparison remains one of the strongest pieces of evidence supporting Selank’s therapeutic profile, though the study was conducted in a Russian clinical setting with limited Western replication. These modulatory mechanisms contrast with the receptor-specific approaches seen in peptides like PT-141 or the GH-axis compounds such as ipamorelin and sermorelin.

Cognitive & Nootropic Support Context

The cognitive and nootropic support relevance of Selank operates through an indirect but well-characterised pathway: anxiety impairs cognition, and anxiolysis without sedation restores it. Unlike benzodiazepines — which reduce anxiety at the cost of cognitive performance — Selank’s non-sedating anxiolytic profile means cognitive function is preserved or enhanced under stress conditions.[1][3] This positions Selank nootropic effects as a secondary benefit of its primary anxiolytic mechanism rather than a direct cognitive enhancement.

Panikratova et al. (2020) studied the functional connectomics of Selank alongside Semax (another Russian-developed neuropeptide), examining how these neuropeptides influence brain network connectivity. The study documented changes in functional connectivity patterns consistent with improved cognitive processing efficiency under Selank.[4] While Semax targets a different neuropeptide pathway (melanocortin-derived), the comparative framework highlights Selank’s distinct cognitive and nootropic support profile — anxiolytic-driven rather than directly stimulatory. This mechanism differs fundamentally from peptides in the GH-axis family like CJC-1295 or tesamorelin, which support cognition indirectly through metabolic and neuroprotective pathways.

Neuroprotection Context

Selank’s neuroprotection profile emerges from two converging pathways: its immunomodulatory heritage and its anti-stress activity. Kolomin et al. (2014) demonstrated that Selank modulates the expression of inflammation-related genes, including IL-6 and other cytokine pathways, establishing a direct link between the peptide and neuroinflammatory regulation.[5] Given the increasingly recognised role of chronic neuroinflammation in neurodegenerative processes, this immunomodulatory activity positions Selank within the broader neuroprotection research landscape alongside compounds like GHK-Cu and BPC-157 that also influence inflammatory signalling.

Konstantinopolsky et al. (2022) extended the neuroprotective narrative by demonstrating that Selank attenuates aversive signs of morphine withdrawal in animal models.[6] This finding suggests modulatory effects on stress-related neural circuits and addiction pathways — areas where neuroprotective intervention may have significant implications. The anti-stress properties documented across multiple studies may confer neuroprotective benefit through reduced excitotoxicity and cortisol-mediated neuronal damage, though these mechanistic links remain to be fully elucidated. The peptide’s neuroprotective approach differs from that of Pal-GHK and TB-500, which operate through tissue repair and regenerative pathways.

Selank Benefits

The Selank benefits profile reflects its unique position as a tuftsin-derived anxiolytic neuropeptide with dual neuroimmune activity:

• Anxiolytic without sedation or dependence: Clinical comparison with phenazepam demonstrated comparable anxiety reduction without the cognitive impairment, sedation, or withdrawal symptoms associated with benzodiazepines.[3]
• Nootropic under stress: By reducing anxiety without impairing cognition, Selank may enhance cognitive performance in stress conditions — a secondary benefit of its primary anxiolytic mechanism.[1][4]
• Immunomodulatory activity: Retains tuftsin’s immunomodulatory properties, modulating cytokine expression (IL-6) and inflammatory gene dynamics — a feature absent from conventional anxiolytics.[2][5]
• No withdrawal symptoms reported: Across clinical studies, no dependence or withdrawal effects have been documented — a significant distinction from benzodiazepines and many other anxiolytic compounds.[3]
• Regulatory approval in Russia: One of the very few peptide-based compounds to achieve clinical approval specifically for anxiety disorders, providing a level of regulatory validation uncommon in the peptide research space.
• Unique dual anxiolytic-immune mechanism: The combination of tuftsin-derived immunomodulation with GABAergic/monoaminergic anxiolysis is genuinely novel — no other approved anxiolytic operates through this neuroimmune bridge.[1][2]

Selank Side Effects

The Selank side effects profile is notably benign compared to conventional anxiolytics, though this must be contextualised against the limitations of the available evidence base:

• No sedation: Unlike benzodiazepines, Selank does not produce drowsiness or psychomotor impairment in clinical studies — this is one of its defining pharmacological features.[3]
• No dependence or withdrawal: No cases of dependence, tolerance, or withdrawal symptoms have been reported across published clinical data.[3]
• Mild fatigue: Rarely reported in some studies, generally transient and self-resolving.
• Limited Western safety data: Most tolerability information comes from Russian clinical trials. Independent Western replication of safety profiles is sparse, meaning the full side effect spectrum may not be captured in the English-language literature.

The Selank side effects profile is one of the compound’s strongest selling points, but it should be interpreted cautiously. The absence of reported adverse effects may reflect genuine tolerability, small study populations, publication bias in Russian-language journals, or some combination of these factors. Compared to the well-characterised side effect profiles of compounds like semaglutide or liraglutide — where large Western RCTs have mapped adverse events in detail — the Selank safety dataset remains thin by international standards.

Half-Life

Selank has a short plasma half-life, estimated at several minutes — characteristic of small peptides vulnerable to enzymatic degradation. However, the Pro-Gly-Pro C-terminal extension provides meaningful improvement over native tuftsin’s extremely rapid clearance. This glyproline tail is a deliberate pharmacokinetic design feature: the Pro-Gly-Pro motif is known to confer resistance to peptidases while also possessing independent neuropeptide activity.[1]

The short half-life positions Selank alongside other rapidly-cleared peptides like gonadorelin and sermorelin, where the downstream biological effects — changes in gene expression, neurotransmitter modulation, immune signalling — persist substantially longer than the peptide’s circulating presence. Clinical use in Russia has employed intranasal delivery, which provides rapid absorption and partially circumvents first-pass hepatic metabolism.

Limits of Current Evidence

• Russian-language literature dominance: The majority of clinical data for Selank is published in Russian-language journals, limiting accessibility and peer review by the broader international research community.
• Limited Western replication: While the compound holds Russian regulatory approval, no large-scale Western RCTs have independently replicated its clinical efficacy or safety profile.
• Not FDA/EMA approved: Selank has not pursued regulatory approval outside Russia/CIS. Unlike semaglutide, tirzepatide, or tesamorelin — which have undergone rigorous Western regulatory review — Selank’s approval pathway followed Russian regulatory standards.
• Small study populations: Most published studies involve relatively small sample sizes, limiting statistical power and generalisability.
• Mechanism not fully elucidated: While the GABAergic and monoaminergic effects are documented, the precise molecular targets and signalling cascades remain to be fully characterised. The Selank tuftsin immunomodulatory angle is better understood than its anxiolytic specifics.
• Publication bias considerations: The predominantly Russian evidence base may be subject to publication bias patterns different from those in Western peer-reviewed literature.

Verdict

Selank represents an innovative approach to anxiolytic design — building on the endogenous immunopeptide tuftsin to create a compound with dual anxiolytic and immunomodulatory properties. Its structural elegance is genuine: using a naturally occurring immune signalling peptide as a scaffold for neuropeptide drug design is conceptually compelling, and the clinical data from Russia supports its anxiolytic efficacy.[1][2][3]

The Selank vs Semax comparison illustrates its niche: while Semax targets the melanocortin pathway for cognitive enhancement, Selank targets the neuroimmune interface for anxiolysis.[4] The absence of sedation and dependence — consistently reported across clinical studies — is its most distinctive and valuable feature, differentiating it from the benzodiazepine class in a clinically meaningful way.[3]

However, the limited Western peer-reviewed data means the evidence base doesn’t meet the standards researchers typically expect for confident conclusions. This Selank review of the available literature confirms that the Russian clinical approval provides regulatory validation, but it is not equivalent to the FDA or EMA review processes that compounds like retatrutide or tirzepatide have undergone. For now, Selank should be evaluated as a promising but incompletely validated anxiolytic neuropeptide — one where the concept is compelling, the preliminary data is encouraging, and the independent replication is still pending.

FAQ

What is Selank?

Selank is a synthetic heptapeptide based on tuftsin — an endogenous immunomodulatory tetrapeptide — with a Pro-Gly-Pro stabilising extension. Developed by the Institute of Molecular Genetics at the Russian Academy of Sciences, it is classified as an anxiolytic neuropeptide with dual anxiolytic and immunomodulatory properties. It is approved in Russia as a nasal spray for anxiety disorders.[1]

Is Selank approved anywhere?

Yes. Selank has been approved in Russia and CIS countries as an anxiolytic nasal spray since 2009. It is not approved by the FDA, EMA, or any other Western regulatory agency. Its Russian approval provides a level of clinical validation, though the regulatory standards differ from Western approval pathways.[3]

What is the difference between Selank and Semax?

Both are synthetic neuropeptides developed at Russian research institutes, but they target different pathways. Selank is a tuftsin analog that primarily provides anxiolytic and immunomodulatory effects through GABAergic and monoaminergic modulation. Semax is an ACTH(4-7) analog that primarily targets the melanocortin pathway for cognitive enhancement and neuroprotection. They are sometimes studied together as complementary neuropeptides.[4]

Does Selank cause sedation?

No. One of Selank’s defining features is that it produces anxiolytic effects without sedation or psychomotor impairment. In clinical comparisons with the benzodiazepine phenazepam, Selank showed comparable anxiety reduction without the sedative side effects.[3]

Is Selank addictive?

No dependence, tolerance, or withdrawal symptoms have been reported in published clinical studies of Selank. This distinguishes it from benzodiazepines and many other conventional anxiolytics, which carry well-documented dependence risks.[3]

What is tuftsin and how does it relate to Selank?

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide produced during the enzymatic cleavage of immunoglobulin G. It plays roles in macrophage activation, phagocytosis, and immune regulation. Selank is a synthetic analog that extends the tuftsin sequence with Pro-Gly-Pro, providing metabolic stability and neuropeptide activity while retaining the immunomodulatory properties of the parent peptide.[2]

Is Selank FDA approved?

No. Selank has not received FDA approval for any indication and has not entered the FDA regulatory pathway. It is approved only in Russia and CIS countries. Outside these jurisdictions, it is classified as a research compound. It is not a controlled substance internationally.

References

1. Vyunova TV, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741
2. Siebert A, et al. Tuftsin — Properties and Analogs. Curr Med Chem. 2017;24(34):3711-3727. PMID: 28745220
3. Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr. 2014;114(7):17-22. PMID: 25176261
4. Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID: 32342318
5. Kolomin T, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-58. PMID: 24291245
6. Konstantinopolsky MA, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):785-789. PMID: 36322304

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Selank is not approved by the FDA for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.